PEspeaks

Jul 12, 2012
Pharmaceutical Executive
The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?
Jul 11, 2012
Pharmaceutical Executive
It may surprise some working in the industry, but pharmaceutical companies, in particular those in Europe, rank among the world’s best online corporate communicators, writes David Bowen.
Jul 10, 2012
Pharmaceutical Executive
Last month, Pharm Exec, the Tufts Center for the Study of Drug Development and software vendor Clear Trial brought companies together for an editorial exchange on current challenges in budgeting and spend for clinical trials.
Jul 06, 2012
Pharmaceutical Executive
Big pharma talks a lot about the changing business model and placing a new emphasis on patients, but the fact remains that quantity of medicines sold, not quality of care provided, is how to get paid (and how to keep investors happy).
Jul 02, 2012
Pharmaceutical Executive
EFPIA president Andrew Witty is hoping that the deepening European economic crisis will impel European leaders towards more courageous and radical solutions, writes Reflector.
Jun 29, 2012
Pharmaceutical Executive
If you’re like me, you probably bounded out of bed on Thursday morning, took in all the news you could find about the Supreme Court and healthcare reform…and then you waited.
Jun 28, 2012
Pharmaceutical Executive
It’s back to business for pharma and biotech companies. The main result of the Supreme Court decision upholding the Affordable Care Act (ACA) is that it ends all the rampant speculation and uncertainty about the future shape of the U.S. healthcare system.
Jun 25, 2012
Pharmaceutical Executive
Patients who live for many years following a cancer diagnosis will likely require additional support, and a whole new kind of follow-up care.
Jun 20, 2012
Pharmaceutical Executive
Legislation fails to establish a national track-and-trace system, but tackles shortages, orphans. House and Senate leaders announced final agreement June 18, 2012 on legislation that authorizes industry user fees to support Food and Drug Administration regulatory programs.
Jun 19, 2012
Pharmaceutical Executive
Rodney King died on Sunday, but his famous question lives on: “Can we all get along?” At BIO 2012, the proposition seems to be: “Can we all just collaborate?”
native1_300x100
lorem ipsum